NTRP Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$6.83median target· current $1.62 (+321.6%)3 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
19 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.360.0% YoY
Profit margin-290.0%CONSUMER CYCLICAL
Market cap$24.2MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 5.91
- P/S (TTM)
- 4.81
- EV/EBITDA
- -0.57
Profitability & growth
- ROE (TTM)
- -260.8%
- Operating margin
- -200.7%
- Revenue growth YoY
- 946.0%
- Dividend yield
- —
- Beta
- 1.59
Last earnings
Jul 15, 2026 · Estimate $-0.22 · Reported $-0.22
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About NextTrip Inc
Company profileNeurotrope, Inc., a biopharmaceutical company, is focused on developing a product platform for the treatment of Alzheimer's disease. The company is headquartered in New York, New York.
Classification
- Sector
- Consumer Cyclical
- Industry
- Travel Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3900 PASEO DEL SOL, SANTA FE, NM
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$24.2M
Shares outstanding$14.9M
52W high$5.20
52W low$1.61
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent